Literature DB >> 2206997

Effect of recombinant human erythropoietin on anticancer drug-induced anaemia.

T Matsumoto1, K Endoh, K Kamisango, K Akamatsu, K Koizumi, M Higuchi, N Imai, H Mitsui, T Kawaguchi.   

Abstract

Anaemia was induced in rats with fluorouracil (5-FU) or cisplatin (CDDP) and the mechanisms of anaemia induction were analysed. Furthermore, the therapeutic effects of recombinant human erythropoietin (rHu Epo) on these anticancer drug-induced anaemias were investigated. In 5-FU-induced anaemia, marked serum erythropoietin (Epo) elevation was observed in inverse correlation to blood Hb concentration and Hb concentration rapidly recovered to normal levels. On the other hand, in CDDP-induced anaemia, serum Epo elevation was modest and the lowered Hb concentration persisted longer. Treatment with rHu Epo significantly improved both anticancer drug-induced anaemias but rHu Epo was more effective on CDDP-induced anaemia. These results suggest that rHu Epo might be useful for the therapy of anaemia associated with anticancer chemotherapy.

Entities:  

Mesh：

Substances：

Year:  1990        PMID： 2206997     DOI： 10.1111/j.1365-2141.1990.tb07783.x

Source DB:  PubMed          Journal:  Br J Haematol        ISSN： 0007-1048            Impact factor:   6.998


  9 in total

1.  Plasma erythropoietin concentrations in patients receiving intensive platinum or nonplatinum chemotherapy.

Authors:  R Canaparo; F Casale; E Muntoni; G P Zara; C Della Pepa; E Berno; N Pons; G Fornari; M Eandi
Journal:  Br J Clin Pharmacol       Date:  2000-08       Impact factor: 4.335

Review 2.  Anemia in Pediatric Kidney Transplant Recipients-Etiologies and Management.

Authors:  Anne Kouri; Shanthi Balani; Sarah Kizilbash
Journal:  Front Pediatr       Date:  2022-06-20       Impact factor: 3.569

3.  Cisplatin-associated anemia: an erythropoietin deficiency syndrome.

Authors:  P A Wood; W J Hrushesky
Journal:  J Clin Invest       Date:  1995-04       Impact factor: 14.808

Review 4.  Pharmacological approaches to reduce perioperative transfusion requirements in the aged.

Authors:  T Tasaki; H Ohto; R Motoki
Journal:  Drugs Aging       Date:  1995-02       Impact factor: 3.923

5.  Pharmacodynamic model for chemotherapy-induced anemia in rats.

Authors:  Sukyung Woo; Wojciech Krzyzanski; William J Jusko
Journal:  Cancer Chemother Pharmacol       Date:  2007-09-22       Impact factor: 3.333

6.  Effects of chemotherapeutic and immunosuppressive drugs on the production of erythropoietin in human hepatoma cultures.

Authors:  M Wolff; W Jelkmann
Journal:  Ann Hematol       Date:  1993-01       Impact factor: 3.673

7.  Clinical application of recombinant human erythropoietin for treatments in patients with head and neck cancer.

Authors:  M Tsukuda; I Mochimatsu; T Nagahara; T Kokatsu; S Sawaki; A Kubota; M Furkawa; Y Arai
Journal:  Cancer Immunol Immunother       Date:  1993       Impact factor: 6.968

8.  Cisplatin-associated anaemia treated with subcutaneous erythropoietin. A pilot study.

Authors:  S Cascinu; A Fedeli; S L Fedeli; G Catalano
Journal:  Br J Cancer       Date:  1993-01       Impact factor: 7.640

9.  Toxicological and tumoricidal evaluations of a new platinum complex, (-)-(R)-2-aminomethylpyrrolidine(1,1-cyclobutanedicarboxylato+ ++)platinum( II) monohydrate, in rats.

Authors:  K Akamatsu; K Endo; T Matsumoto; K Morikawa; M Koizumi; K Koizumi; H Mitsui
Journal:  Jpn J Cancer Res       Date:  1991-06
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.